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Abstract
Trypanosoma cruzi, etiological agent of Chagas’ disease, has a complex life cycle which involves the
invasion of mammalian host cells, differentiation and intracellular replication. Here we report the first
insights into the biological role of a poly(ADP-ribose) glycohydrolase in a trypanosomatid (TcPARG). In
silico analysis of the TcPARG gene pointed out the conservation of key residues involved in the
catalytic process and, by Western blot, we demonstrated that it is expressed in a life stage-dependant
manner. Indirect immunofluorescence assays and electron microscopy using an anti-TcPARG antibody
showed that this enzyme is localized in the nucleus independently of the presence of DNA damage or
cell cycle stage. The addition of poly(ADP-ribose) glycohydrolase inhibitors ADP-HPD (adenosine
diphosphate (hydroxymethyl) pyrrolidinediol) or DEA (6,9-diamino-2-ethoxyacridine lactate
monohydrate) to the culture media, both at a 1 µM concentration, reduced in vitro epimastigote
growth by 35% and 37% respectively, when compared to control cultures. We also showed that ADP-
HPD 1 µM can lead to an alteration in the progression of the cell cycle in hydroxyurea synchronized
cultures of T. cruzi epimastigotes. Outstandingly, here we demonstrate that the lack of poly(ADP-
ribose) glycohydrolase activity in Vero and A549 host cells, achieved by chemical inhibition or iRNA,
produces the reduction of the percentage of infected cells as well as the number of amastigotes per
cell and trypomastigotes released, leading to a nearly complete abrogation of the infection process.
We conclude that both, T. cruzi and the host, poly(ADP-ribose) glycohydrolase activities are important
players in the life cycle of Trypanosoma cruzi, emerging as a promising therapeutic target for the
treatment of Chagas’ disease.
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Introduction
Poly-ADP-ribose (pADPr) signaling is common to
various nuclear processes related to DNA metabolism.
As a reversible modification of many nuclear proteins,
it is regulated by a delicate balance of synthesis and
degradation. Poly(ADP-ribosyl) ation is an early cellular
response to DNA damage and is a concerted and
dynamic process: poly(ADP-ribose) polymerases
(PARPs) catalyze the transfer of ADP-ribose (ADPr) and
attach them to specific target proteins, whereas
poly(ADP-ribose) glycohydrolase (PARG) represents the
main pADPr hydrolyzing activity in the cell to ADPr
units. Poly(ADP-ribose) chains are thus transient, and it
is suggested that once other proteins have localized to
the damage site, pADPr must be removed before repair
can take place. Poly(ADP-ribose) glycohydrolase (PARG)
is the endo-
exoglycohydrolase that cleaves glycosidic bonds,
reversing the action of PARP enzymes and returning
proteins to their native state [1–9].
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The precise biological functions of PARG involve the
pADPr cycling required for structural chromatin
remodeling during DNA repair, transcription, DNA
replication and various cell death pathways, ranging
from necrosis to apoptosis and autophagy [1,7,10]. In
addition, some authors have suggested that the
concerted action of PARG and ADP-ribose
pyrophosphorylase is capable of generating ATP from
ADP-ribose units [11].
Trypanosoma cruzi, the etiologic agent of Chagas’
disease, is transmitted by insect vectors when these
blood-sucking triatomines deposit on the animal or
human skin their feces, containing the infective form of
the parasite. Establishment of infection by T. cruzi
depends on a series of events where cell invasion is a
crucial step. Great progress has been made towards
understanding the mammalian cell invasion by this
pathogen, but still a great deal of work needs to be
done in order to draw a complete picture of this
complex process.
We have previously characterized PARP from
Trypanosoma cruzi (TcPARP) and, as opposed to
humans and other organisms, both T. cruzi and
Trypanosoma brucei have only one PARP [12].
Exposure of T. cruzi epimastigotes to DNA-damaging
agents shows a drastic increase in the levels of pADPr
in the nucleus, thus confirming pADPr synthesis in vivo
and suggesting a physiological role for PARP in the
trypanosomatid DNA repair signaling process [13]. We
have also demonstrated that inhibition of PARP reduces
epimastigote growth in culture and affects cell infection
by T. cruzi [14]. Trypanosoma cruzi PARG (TcPARG) has
been identified in our laboratory using a database
search strategy in a way similar to that described for
trypanosomatid PARPs. Here we demonstrate that
inhibition of TcPARG causes a delay in cell cycle
progression and what is more significant, PARG from
the host cell has shown to be essential for the vital
cycle of this parasite, pointing out this process requires
pADPr degradation and therefore, can be considered as
a plausible approach for hindering the infection.
Materials and Methods
Materials
All restriction endonucleases and DNA Polymerase
Taq were from New England Biolabs Inc., Beverly, MA.
Bacto-tryptose and liver infusion were from Difco
Laboratories, Detroit, MI. All other reagents were
purchased from Sigma Chemical Co., St. Louis, MO.
Parasites cultures and cell extracts
Trypanosoma cruzi epimastigote forms (CL Brener)
were cultured at 28 °C for 7 days in liver infusion
tryptose (LIT) medium (5 g/l liver infusion, 5 g/l bacto-
tryptose, 68 mM NaCl, 5.3 mM KCl, 22 mM Na2HPO4,
0.2% (W/V) glucose, and 0.002% (W/V) hemin)
supplemented with 10% (V/V) FCS, 100 U/ml penicillin
and 100 mg/l streptomycin. Cell viability was assessed
by direct microscopic examination. Cells were
harvested by centrifugation at 850xg and 4 °C, washed
three times with PBS and resuspended in buffer A: 50
mM Tris–HCl, pH 8.0, 1.0 mM EDTA, 10% (V/V) glycerol,
10 mM 2-mercaptoethanol, containing protease
inhibitors: 1 µg/ml trans-epoxysuccinyl-L-
leucylamido(4-guanidino) butane (E-64), 1 mM
pepstatin A, 1 mM phenylmethylsulfonyl fluoride
(PMSF), and 0.1 mM Na-pTosyl-L-lysine chloro-methyl
ketone (TLCK). Cells were lyzed in an Ultrasonic
Processor Model W385 Sonicator (Heat Systems-
Ultrasonic Inc, Plainview, IL, NY, USA) and the whole
extract obtained was used as a protein source for
Western blot or Dot blot analysis.
Preparation of DNA and RNA from T. cruzi
DNA from T. cruzi epimastigotes form was prepared
following the protocol previously described by Pereira
et al. [15], its integrity assessed by TAE-agarose gel
electrophoresis and quantified by spectrophotometry
using NanoDrop 1000 (Thermo, Fisher Scientific,
Waltham, MA, USA). Total RNA was obtained using the
Total RNA isolation (TRIzol) reagent (Invitrogen)
according to the manufacturer’s instructions. RNA
integrity was assessed by MOPS Formaldehyde Agarose
gel electrophoresis and quantified by
spectrophotometry using NanoDrop.
Southern and Northern Blot analysis
Southern blot analysis was performed using 5 µg of
DNA previously digested with restriction
endonucleases. After the DNA was electrophorezed in a
1% agarose gel, it was transferred to a Hybond N+
Nylon membrane (Amersham Pharmacia Biotech,
Piscataway, USA) and hybridized at 65 °C in Church’s
buffer [1% (W/V) BSA, 7% (W/V) SDS, 1 mM EDTA pH 8,
0.5% (W/V) Na2HPO4 with a specific probe
corresponding to the whole TcPARG gene, obtained by
PCR. The analysis by Northern Blot was carried on a 1%
formaldehyde-agarose gel on 10 µg of total RNA. After
electrophoresis, it was transferred and hybridized as
described in the Southern blot analysis. Blots were
subjected to sequential stringent washes at 65 °C and
either exposed to AGFA CPBU NEW films (AGFA Gevaert
N.V., Belgium) or scanned using a phosphoimager
STORM 820 (Amersham, Pharmacia, USA). All probes
were labeled with [32P] dCTP using Random Primer
Extension Labeling System (PerkinElmer LAS, Inc.,
Boston, MA, USA), according to the manufacturer’s
instructions.
Culture synchronization and cell cycle analysis
Trypanosoma cruzi epimastigote cultures were
synchronized as previously described by Galanti and
co-workers [16]. Briefly, cultures with a density of 107
parasites/ml were incubated in the presence of
hydroxyurea (HU) 15 mM for 20 hs. After the incubation
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period, parasites were washed 3 times with PBS and
resuspended in 1 volume of fresh LIT medium. Samples
were drawn periodically and analyzed by flow
cytometry.
The method used for DNA labeling for flow cytometry
analysis was based on the use of propidium iodide (PI,
Sigma Chemical Co., St. Louis, MO) staining. The PI
fluorescence of individual cell nuclei was measured
using a BD FACSAriaTM flow cytometer (Becton
Dickinson, San Jose, CA). At least 104 cells of each
sample were analyzed. All measurements were made
using the same instrument settings.
Subcellular localization
Immunofluorescence.  Anti-TcPARG antibodies
were obtained as previously described [13]. Parasites
were fixed with 3.8% (W/V) formaldehyde in PBS at 4°C,
permeabilized with fresh PBS-0.1%Triton X-100 and
blocked for 1 h at room temperature. PARG was
detected with 1:500 primary antibody followed by
1:600 Alexa Fluor 488 goat anti-mouse IgG antibody
(Invitrogen). Excess of antibody was removed by 3×5-
min washes in PBS, and the nuclei were stained with
2 µg/ml DAPI (Sigma) in PBS. Coverslips were washed
with distilled water and mounted in Mowiol and then
visualized using an Olympus BX41 microscope.
Electron microscopy.  About 108 epimastigote cells
were harvested and washed twice in PBS. The parasites
were fixed in PBS 2.5% glutaraldehyde, 4%
formaldehyde, pH 7.3 for 1 h and then embedded in
epoxy resin, sectioned, and stained using 1:50 mouse
polyclonal TcPARG antibody followed by 1:100 anti-
mouse antibody conjugated with 10-nm gold particle
(GE healthcare, Little Chalfont, Buckinghamshire, UK).
Images were obtained on a Zeiss EM 10 C transmission
electron microscope operating at 80 kV.
Western blot and Dot Blot analysis
For Western blot analysis, the protein in the whole
cell lysate was quantified by Bradford and 35 µg of
protein were electrophorezed on 10% SDS-PAGE gel
and transferred to Amersham Hybond-ECL
nitrocellulose membrane (GE healthcare, Little
Chalfont, Buckinghamshire, UK), according to the
manufacturer’s instructions. TcPARG was detected with
an anti-TcPARG (1:10000) specific antiserum, followed
by anti-mouse horseradish peroxidase-conjugated
antibody (1:6000) (Kirkegaard Perry Laboratories, Inc.).
β-tubulin was used as loading control. For Dot blot
analysis, 5 µg of protein was spotted onto an
Amersham Hybond-ECL nitrocellulose membrane (GE
healthcare) by using a Minifold Dot Blot System
(Schleicher Schuell, Inc.). Immunodetection of ADP-
ribose polymers was carried out using mouse
polyclonal antibody directed against the pADPr
(1:5000) (BD), followed by anti-rabbit horseradish
peroxidase-conjugated antibody (1:6000) (Kirkegaard
Perry Laboratories, Inc.).
The signal was detected with the Western Lightning
Plus-ECL kit (PerkinElmer).
In vivo inhibition of Trypanosoma cruzi PARG
For the assessment of the effect of DEA (6,9-
diamino-2-ethoxyacridine lactate monohydrate)
(Trevigen, Inc.) on PARG activity, T. cruzi epimastigotes
were grown in LIT complete medium for 4 days up to a
parasite density of 107 parasites/ml in the absence or
presence of DEA. Cells were harvested by
centrifugation at 1500×g, washed with PBS and the
whole extract, obtained as described above, was used
for Dot blot assay.
In the case of ADP-HPD (adenosine diphosphate
(hydroxymethyl) pyrrolidinediol) inhibitor (Calbiochem),
T. cruzi epimastigotes were grown in LIT complete
medium for 4 days up to a parasite density of 107
parasites/ml, collected by centrifugation at 750×g for 5
minutes and resuspended in PBS-Glucose 2%. Parasites
were pre-incubated in the presence of the PARG
inhibitor, ADP-HPD, for 30 minutes and treated with
300 µM hydrogen peroxide for 10 minutes. Cells were
washed to remove the oxidizing agent. After 30 and 60
minutes post-agent removal, parasites were harvested
and lysed and the whole extract used for Dot blot assay
as described above.
Growth inhibition assays
T. cruzi epimastigotes were grown in LIT complete
medium for 4 days up to a parasite density of 107
parasites/ml. The culture was then placed in 96-well
sterile plates in 100 µl aliquots and PARG inhibitors
(DEA or ADP-HPD) were added to previous digitonin-
permeabilized-cells. DMSO was used as a control at 1%
V/V concentration. The number of epimastigotes was
determined daily by counting formaldehyde-fixed
parasites in a Neubauer chamber. In all experiments
performed, conditions were tested in triplicates. Day 0
corresponds to the day in which the cultures were
placed in the plate and the inhibitors added.
Significance of the results was analyzed with one-way
ANOVA using GraphPad Prism version 5.03 for Windows
(GraphPad Software).
Trypanosoma cruzi infection of Vero and A549
cells.  Vero cells were cultured in D-MEM medium
(Gibco), supplemented with 2 mM L-glutamine, 10%
(V/V) FCS, 100 U/ml penicillin and 100 mg/l
streptomycin. Wild type and PARG silenced (shPARG)
pulmonary adenocarcinoma A549 cell lines were
provided by Dr. Virág and Dr. Erdélyi, from the
University of Debrecen, Hungary [8]. A549 cells were
grown in RPMI-1640 medium (Gibco), supplemented
with 2 mM L-glutamine, 1 mM Sodium Pyruvate, 10%
(V/V) FCS, 100 U/ml penicillin and 100 mg/l
streptomycin.
Trypomastigotes were collected by centrifugation of
the supernatant of previously infected cultures at
1500×g at room temperature for 7 minutes and
Importance of PARG for T.cruzi Infection
PLOS ONE | www.plosone.org 3 June 2013 | Volume 8 | Issue 6 | e67356
incubated for 3 hours at 37 °C in order to allow the
trypomastigotes to move from the pellet into the
supernatant. After this period, the supernatant was
collected and trypomastigotes were counted in a
Neubauer chamber. The purified trypomastigotes were
pre-incubated in the presence or absence of 1 µM DEA
for 30 minutes and then used to infect new monolayers
of Vero or A549 cells. For this, 50 trypomastigotes/cell
were added to the medium of 24 hour-old monolayers
and incubated for 24 hours at 37 °C, after which they
were removed by changing the cell culture medium.
The infection was allowed to proceed and growth
medium was changed periodically during the first 5
days. In the PARG inhibited samples, DEA was kept in
the growth medium at 1 µM throughout the
experiment. At the indicated days, cells were fixed and
stained by May Grünwald Giemsa technique. Cells were
visualized using an Olympus BX41 microscope.
Amastigotes and host cells were counted using the
ImageJ software in at least 7 microscopic fields.
Alternatively, trypomastigotes in the supernatant of the
cell cultures were counted without prior fixation on a
Neubauer Chamber at the indicated days. All
experiments were performed in triplicates. Significance
of the results was analyzed with two-way ANOVA using
GraphPad Prism version 5.03 for Windows (GraphPad
Software).
For the experiments in which only trypomastigotes
were subjected to the effect of DEA, this infective form
was obtained as above described and incubated in the
presence of DEA for 4 hours, then collected by
centrifugation and resuspended in fresh medium
without DEA. These trypomastigotes were used to
infect wild type Vero cells in the absence of DEA,
following the infection protocol recently addressed. At
72 and 96 hours post-infection, cells were fixed and
stained by May Grünwald Giemsa technique.
Results
In silico analysis of TcPARG
T. cruzi PARG was identified in our laboratory using a
database search strategy in a way similar to that we
have previously described for trypanosomatid PARPs
[12]. The search carried on the T. cruzi databases
showed one possible ORF coding for a putative PARG
and the corresponding sequence was annotated in
GenBank under Accession Number DQ679799. A similar
search performed on the Trypanosoma brucei genomic
database showed a putative sequence
(Tb09.211.3760), but in the related trypanosomatid
Leishmania major no positive hits were identified,
outcome that agrees with the lack of a gene coding for
poly(ADP-ribose) polymerase. Based on the information
obtained from the databases, TcPARG codes for a
protein of 540 amino acids. We compared T. cruzi and
T. brucei glycohydrolase amino acid sequences by
using alignments that cover the full length of the
sequences (global alignments), and found 46.5% of
identity and 60% of similarity. In addition, sequence
alignment of the PARG catalytic domain fragment,
known as PARG signature, showed a higher
conservation of this motif in trypanosomatid PARGs
(61.7% and 68.3% of identity when comparing TcPARG
with Homo sapiens PARG and the orthologous
sequence in Drosophila melanogaster, respectively).
The three essential acidic residues (D-E-E) identified
within the PARG catalytic fragment [17] are present in
both TcPARG and TbPARG (Figure 1, asterisks). These
two consecutive glutamates and a glycine (Figure 1,
underlined) were also reported as key residues by
Slade et al. [18]. In addition, a tyrosine residue (Figure
1, diamond) implicated in the binding to the PARG
inhibitor ADP-HPD is also present in TcPARG. When a
wide region including the complete PARG catalytic
motif was aligned, the identity between T. cruzi and T.
brucei PARG value was 51.5% and about 30% when
compared to the other organisms (Table 1).
Genetic organization and expression of PARG
in Trypanosoma cruzi
The copy number of PARG genes was determined by
Southern blot; results show that TcPARG is a single-
copy gene (data not shown), which is consistent with
the results obtained by searching at the GeneDB
database (http://www.genedb.org). We found the
presence of only one transcript by Northern blot
analysis on epimastigote mRNA obtained at different
time points throughout the cell cycle in synchronized
cultures, using the full length sequence as a probe
(Figure S1 A). The analysis of the expression of the
TcPARG protein on synchronized epimastigotes also
showed its presence in every cell cycle phase, as
evidenced by Western blot using specific anti-TcPARG
antisera. It can be seen that an increase in PARG
protein levels occurs up to eight hours after
hydroxyurea relief. Later, lower molecular mass bands
were also detected (Figure S1 B). TcPARG mRNA
relative abundance over the course of T. cruzi life-cycle
was evaluated as well, by using the
Gene Expression Omnibus database
(www.ncbi.nlm.nih.gov/geo, DataSets: GSE14641)
generated by Minning and co-workers [19]. This study
showed that in mammalian-host stages (amastigotes
and trypomastigotes) TcPARG mRNA is down-regulated,
while in the insects stage form (epimastigotes) it is up-
regulated (Figure 2 A). The results of these analyses
were compared to the protein expression pattern
determined by Western blot in these three life-cycle
stages of T. cruzi. In accordance, we found a strong
correlation between the specific transcript abundance
and protein relative levels (Figure 2 B). Note that the
expression of TcPARG shows consistency between the
stages of the same host, despite the fact that previous
genomic studies of kinetoplastids have found a low
proportion of their genomes to be stage regulated.
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TcPARG is targeted to the nucleus
Using previously obtained specific antibodies [13], we
assessed the localization of the enzyme in the parasite
by immunofluorescence and electron microscopy.
TcPARG was present in the nucleus both in the absence
(Figure 3 A–D) or presence of DNA damage (data not
shown). These results were corroborated on a
transgenic T. cruzi line expressing a copy of TcPARG
which had been fused to the RED protein (Figure S2).
Similar results were obtained when we attempted to
ascertain the localization of TcPARG in different cell
cycle stages using the antibody directed against
TcPARG on wild type epimastigotes coming from
synchronized cultures (Figure S1 C) or in the
intracellular amastigote (data not shown). TcPARG
showed to be localized in the nuclear compartment in
every condition tested. We also examined the
localization of this enzyme by transmission electron
microscopy. Results in Figure 3 E-F show that TcPARG
is localized to the nucleus as can be seen by the high
density of associated immunogold particles (arrows).
We were not able to detect this enzyme in other
subcellular compartment although a slight immunogold
signal was visualized associated to the kinetoplast.
In vivo inhibition of Trypanosoma cruzi PARG
We measured the presence of ADP-ribose polymer in
epimastigotes in culture until the 4th day of growth. As
shown in Figure 4 A, a slight amount of pADPr was
observed in control conditions as a result of
physiological pADPr metabolism during growth. In the
presence of DEA, a known PARG inhibitor, an enhanced
polymer accumulation was observed, probably due to a
lower rate in the catabolism of this molecule (Figure 4
A and C). ADP-HPD, an analogue of the ADP-ribose
product of the PARG-catalyzed reaction, is one of the
most potent and widely used PARG inhibitor, despite its
lack of cell permeability. In order to evaluate the
affectivity of this more specific PARG inhibitor in these
organisms, we measured pADPr formation after
Figure 1.  Amino acid sequence alignment of the PARG signature from different organisms.  The multiple
alignment of the PARG signature amino acid sequences corresponding to T. cruzi PARG (accession number
ABG73229); T. brucei PARG (GeneDB Systematic Name: Tb09.211.3760); C. elegans_1 PARG (accession number
NP_501496) and C. elegans_2 PARG (accession number NP_501508); T. thermophila (accession number EAR94344);
A. thaliana_1 PARG (accession number NP_973578); A. thaliana_2 PARG (accession number AAK72256); D.
discoideum PARG (accession number XP_642024); D. melanogaster PARG (accession number NP_477321); C.
quinquefasciatus PARG (accession number XP_001853435); A. aegypti PARG (accession number XP_001659301); D.
rerio PARG (accession number XP_001338257); X. laevis PARG (accession number NP_001089602); G. gallus PARG
(accession number XP_421502); B. taurus PARG (accession number NP_776563); R. norvegicus PARG (accession
number NP_112629); M. musculus PARG (accession number NP_036090); H. sapiens PARG (accession number
NP_003622); P. abelii PARG (accession number NP_001125086); P. troglodytes PARG (accession number
XP_001139727) was generated with the ClustalW2 program and edited with the BOXSHADE (3.21) software. Colors
used for amino acids background are as follow: white for different residues, black for identical residues, gray for
similar and conserved residues. Asterisk: essential acidic residues D-E-E, underlined: key residues, G and two
consecutive E, and black diamond: important Y residue.
doi: 10.1371/journal.pone.0067356.g001
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genotoxic insult in T. cruzi epimastigotes previously
permeabilized and incubated with this compound.
Figure 4 B shows pADPr formation after epimastigote
treatment with H2O2. It can be seen that the presence
of the inhibitor leads to a higher accumulation of the
polymer after exposure to a genotoxic stimulus (Figure
4 B and D).
Role of PARG in T. cruzi proliferation
To further characterize the importance of PARG in T.
cruzi survival, we evaluated the effect of PARG
inhibitors on epimastigote cell growth in culture. All the
inhibitors assayed at 1 µM concentration were able to
diminish the growth rate in the conditions here tested,
the reduction being 35.7 and 37.5% at day 4 of growth
for ADP-HPD and DEA respectively, as compared to
control conditions without the addition of inhibitor
(Figure 5 A).
When the effect of ADP-HPD was evaluated on cell
cycle progression by flow cytometry, cells incubated in
the presence of PARG inhibitor presented differences in
the percentage of epimastigotes in the S and G2/M-
phases at 8, 10 and 12 hours after the culture was
released from the HU-imposed arrest. While control
cultures showed a constant increase in the fraction of
epimastigotes in the G2/M-phase in the aforementioned
period, the number of cells in this cell cycle phase, as
well as in the S-phase, in PARG-inhibited cultures
remained unaltered throughout this period (Figure 5 B).
Nevertheless, both cultures could continue with cell
cycle progression and entry into a new round of
replication.
Inhibition of PARG interferes with cell invasion
and the progress of infection
The inhibitor DEA was used in in vitro cell infection
experiments, using Vero cell line as host cells. Controls,
in which uninfected cells were incubated in the
presence or absence of DEA, showed that this
compound did not alter the growth of the host cell line
(data not shown). The results in Figure 6 A show that
the percentage of infected cells in control conditions
was about 40% at day two post infection. The level of
infection diminished at day four probably due to a
differential cell division rate and then increased again
as the result of the reinfection process perpetrated by
the trypomastigotes released. This observation was
supported by the presence of trypomastigotes in the
supernatant at day 6 (Figure 6 E). When DEA was
present in the culture medium, not only the percentage
of infected cells was reduced but also the amount of
amastigotes per cell was greatly diminished, avoiding
the establishment of the infection (Figure 6 A and C
and Figure S3). These results suggest that both
invasion and proliferation of intracellular stage of the
parasite could be interrupted in the presence of the
PARG inhibitor.
Since DEA could potentially be inhibiting either the
parasite enzyme or the host cell enzyme, we performed
a similar experiment using the human cell line A549
with stably suppressed PARG (A549 shPARG) as host
cell. Knock down of PARG had no effect on normal cell
growth as was stated by Erderlyi et al. [8] A549
shPARG showed a drastically reduction in both the
percentage of infected cells and in the number of
amastigotes per cell (Figure 6 B and D). The results
Table 1. Identity/similarity percentage of T. cruzi
and T. brucei PARG catalytic domain.
 T. cruzi_PARG T. brucei_PARG
T. cruzi_PARG ------ 51.5/65.1
T. brucei_PARG 51.5/65.1 ------
A. thaliana_1_PARG 26.8/39.1 26.4/38.0
A. thaliana_2_PARG 27.9/39.5 27.5/38.8
C. elegans_1_PARG 24.4/38.6 25.7/41.3
C. elegans_2_PARG 28.2/40.3 26.4/39.8
B. taurus_PARG 32.6/47.7 33.9/47.3
H. sapiens_PARG 32.9/48.8 34.2/47.8
D. melanogaster_PARG 33.9/46.0 33.7/46.6
R. norvegicus_PARG 32.9/48.8 33.7/47.3
M. musculus_PARG 32.9/48.8 33.9/47.6
G. gallus_PARG 32.3/46.5 35.0/47.9
C. quinquefasciatus_PARG 34.3/46.9 34.5/46.2
D. discoideum_PARG 33.6/49.4 30.9/46.2
A. aegypti_PARG 34.0/44.2 34.3/46.9
D. rerio_PARG 29.4/47.2 30.1/46.1
P. abelii_PARG 32.9/48.8 34.2/47.8
X. laevis_PARG 32.0/45.2 35.0/47.7
T. thermophila_PARG 28.7/45.9 26.4/43.6
P. troglodytes_PARG 32.7/48.5 33.2/46.2
T. cruzi and T. brucei PARG catalytic motif amino acid sequences were
aligned with the catalytic regions of PARGs from different organisms.
The optimum alignments were generated using the EMBOSS: needle
online version at the European Bioinformatics Institute which applies the
Needleman-Wunsch global alignment algorithm. T. cruzi PARG
(accession number ABG73229); T. brucei PARG (GeneDB Systematic
Name: Tb09.211.3760); C. elegans_1 PARG (accession number
NP_501496) and C. elegans_2 PARG (accession number NP_501508); T.
thermophila (accession number EAR94344); A. thaliana_1 PARG
(accession number NP_973578); A. thaliana_2 PARG (accession number
AAK72256); D. discoideum PARG (accession number XP_642024); D.
melanogaster PARG (accession number NP_477321); C. quinquefasciatus
PARG (accession number XP_001853435); A. aegypti PARG (accession
number XP_001659301); D. rerio PARG (accession number
XP_001338257); X. laevis PARG (accession number NP_001089602); G.
gallus PARG (accession number XP_421502); B. taurus PARG (accession
number NP_776563); R. norvegicus PARG (accession number
NP_112629); M. musculus PARG (accession number NP_036090); H.
sapiens PARG (accession number NP_003622); P. abelii PARG (accession
number NP_001125086); P. troglodytes PARG (accession number
XP_001139727).
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Figure 2.  Expression of TcPARG throughout the Trypanosoma cruzi life-cycle.  (A) Microarray expression
data for TcPARG over the course of T. cruzi life-cycle. TcPARG mRNA relative abundance was evaluated by using the
transcriptome analysis of different T. cruzi stages available at Gene Expression Omnibus database
(www.ncbi.nlm.nih.gov/geo, DataSets: GSE14641). Shown are mean microarray log2 ratios (stage/reference) for TS
significantly regulated in Trypanosoma cruzi amastigotes (AMA), trypomastigotes (TRYP), epimastigotes (EPI), and
metacyclic trypomastigotes (META). (B) Western blot analysis of the three life-cycle stages of T. cruzi. Protein
extracts (35 µg) of amastigote, epimastigote or trypomastigote stages of T. cruzi were solved in a 10%
polyacrylamide gel, transfer to a nitrocellulose membrane and revealed with an anti-TcPARG (1:10000) specific
antiserum. β-tubulin was used as loading control.
doi: 10.1371/journal.pone.0067356.g002
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obtained in PARG silenced cells showed that the
presence of this enzyme is necessary in the host cell
for the progression of the infection.
As a complementary analysis we evaluated the effect
of TcPARG inhibition by pre-incubation of
trypomastigotes in the presence of DEA for four hours
previous to the initial infection, but the PARG inhibitor
was not added to the cell culture medium afterwards.
The percentage of wild type Vero infected cells showed
no significant differences when compared to control
infection conditions (no pre-incubation of
trypomastigotes or addition of DEA to the culture
medium) at 72 and 96 hs post-infection (data not
shown).
It is worth mentioning that the wild type A549 cell
line showed, at day six after infection, a higher number
of amastigotes per cell than Vero cell cultures in the
absence of DEA (Figure 6 C and D). However, when
A549 cells were treated with DEA, the reduction in the
number of amastigotes per cells was similar to the
results obtained when A549 PARG silenced cells were
infected, showing no further effect over those already
produced by the absence of this enzyme in the host
cell (Figure 6 D and Figure S4). Finally, there was a
clear decrease in the trypomastigote number in all DEA
Figure 3.  Immunolocalization of PARG on Trypanosoma cruzi, CL Brener epimastigotes.  The parasites
were fixed for 25 min with 3.8% (W/V) formaldehyde in PBS at 4°C, permeabilized with fresh PBS - 0,1% Triton
X-100 and blocked for 1 h at room temperature with 5% (W/V) BSA in PBS. (A) Differential interference contrast
(DIC). (B) Cells were counterstained with DAPI to identify nuclear DNA and kinetoplastid DNA. (C) PARG was
detected with 1:500 mouse polyclonal TcPARG antibody followed by 1:600 Alexa Fluor 488 goat anti-mouse IgG
antibody. (D) Merge of PARG and DNA signals show the nuclear localization of this enzyme. Bar: 10 µm. (E–F) For
electron microscopy, epimastigotes were fixed in PBS 2.5% glutaraldehyde, 4% formaldehyde, embedded in epoxy
resin and PARG detected with 1:50 mouse polyclonal TcPARG antibody followed by 1:100 anti-mouse antibody
conjugated with 10-nm gold particle. N: nucleus; K: kinetoplast. Bar: 0.2 µm.
doi: 10.1371/journal.pone.0067356.g003
Importance of PARG for T.cruzi Infection
PLOS ONE | www.plosone.org 8 June 2013 | Volume 8 | Issue 6 | e67356
treated cells and in the silenced PARG cell line, when
compared to their respective controls (Figure 6 E-F).
Interestingly, when the presence of trypomastigotes in
the supernatant culture media of shPARG A549 cells
was evaluated, it showed that DEA treatment
significantly reduced the trypomastigote concentration
(Figure 6 F). Taking into account that the number of
trypomastigotes in the supernatant was the only
affected parameter when PARG silenced cells were
treated with DEA but that pre-incubation of
trypomastigotes in this PARG inhibitor has no effect on
the initial infection effectivity of these parasites on
Vero cells, we hypothesized that DEA could have a
direct effect over T. cruzi amastigote intracellular
replication or amastigote to trypomastigote
differentiation processes, as well as over the host cell.
Discussion
We have previously reported the presence of a
poly(ADP-ribose) polymerase in the trypanosomatid
Trypanosoma cruzi. Moreover we demonstrated that
these parasites posses only one PARP responsible for
the synthesis of these polymers and that poly(ADP-
ribose) metabolism is involved in the cellular response
to the existence of DNA damage in these organisms
[12,13]. In contrast to the large body of information
related to PARP that is nowadays available, there is
less reported data on PARP’s counterpart, poly(ADP-
ribose) glycohydrolase. In the present work, we report
the PARG expression profile during the life cycle of a
kinetoplastid parasite, and relate its activity to cell
proliferation.
Recently, Slade et al. [18] described the first crystal
structure and the catalytic mechanism of the poly(ADP-
ribose) glycohydrolase from Thermomonospora
curvata. The catalytic activity of PARG has been
proposed to relay on the two glutamic acid residues in
the GGG-X6-8-QEE motif (E114 and E115). Although
both residues have been described to be essential for
activity, only E115 is proposed to be directly involved
in the catalysis. Mutation studies in T. curvata PARG
support the notion that E114 would participate in the
correct substrate positioning and binding [18]. Our
homology searches revealed that TcPARG protein
sequence bears the PARG signature (GGG-X6–8-QEE),
which includes the key residues: two consecutive
glutamates (E292 and E293) and a glycine (G282). In
Figure 4.  Inhibition of PARG activity in Trypanosoma cruzi.  (A) Dot Blot analysis of poly(ADP-ribose)
accumulation during epimastigote growth in cultures untreated (Control) or treated with 1 µM of the PARG inhibitor
DEA (DEA) for four days. (B) Dot Blot analysis of poly(ADP-ribose) formation and degradation after a genotoxic
stimulus in untreated epimastigotes (Control) or in parasites preincubated with 1 µM of the PARG inhibitor ADP-HPD
(ADP-HPD) for 30 min. After preincubation, hydrogen peroxide 300 µM was added (0 min), incubated for 10 minutes
at 28°C (10 min) and the oxidizing agent was removed. Samples were obtained at 30 and 60 minutes post agent
removal (indicated as 40 min and 70 min respectively).
Five µg of total protein extract were dotted onto nitrocellulose membrane and an anti-pADPr polyclonal antibody
was used to detect the formed polymers (upper panels). Ponceau Red was used to detect the whole protein sample
in each dot (lower panels). (C–D) Data were normalized to protein content and are shown as the ratio of pADPr to
loading control signals. Representative experiment of three independent assays.
doi: 10.1371/journal.pone.0067356.g004
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Figure 5.  Role of TcPARG in Trypanosoma cruzi epimastigotes proliferation and cell cycle
progression.  A) Effect of the PARG inhibitors ADP-HPD and DEA on T. cruzi growth and survival was determined
by incubating epimastigotes at an initial density of 107 parasites/ml in the continuous presence of inhibitors at 1
µM. The number of epimastigotes was determined daily by counting formaldehyde-fixed parasites in a Neubauer
chamber. All data points were determined in triplicates and shown as means with standard deviation. The
significance of the results versus the control at day 4 was analyzed with t test and indicated in the figure (* p0.05).
B) Effect of ADP-HPD at 1 µM concentration on cell cycle progression of epimastigotes was determined by adding
the inhibitor at the indicated concentration to the culture media of hydroxyurea synchronized parasites after
digitonin permeabilization. Samples were drawn every 2 hours for 14 hours and DNA content was determined by
propidium iodide staining followed by flow cytometry analysis. The percentage of epimastigotes in each cell cycle
phase was determined by setting gates according to the DNA content in the 0 hs of the control sample and
maintained for all other samples. The data were analyzed using the Cyflogic software.
doi: 10.1371/journal.pone.0067356.g005
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Figure 6.  Effect of PARG inhibitors on T. cruzi infection on Vero or A549 host cells.  T. cruzi
trypomastigotes were purified from the supernatant of previously infected cells and preincubated for 30 min in the
respective culture medium in the absence (Control) or presence of 1 µM PARG inhibitor (DEA). Twenty-four hours
Vero, A549 wild type or shPARG (hPARG silenced) cell monolayers were infected with 50 trypomastigotes/cell. The
infection process was followed by microscopic direct visualization. At the indicated days (A and C) or at day 6 post-
infection (B and D), percentage of infected cells and number of amastigotes intracellular were determined on May-
Grünwald Giemsa stained samples. Amastigotes and cells were counted using the ImageJ software in at least 7
fields. The number of trypomastigotes/ml in the supernatant of infected cell cultures was determined by counting
unfixed trypomastigotes in a Neubauer chamber at the indicated days (E) or at day 9 post-infection (F). All points
were determined in triplicates and shown as means with standard deviation. Significance of the result versus the
Control (***p0.001; two way ANOVA) or Wild Type Control (***p0.001; **, p0.01; two way ANOVA) is indicated.
doi: 10.1371/journal.pone.0067356.g006
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addition, a tyrosine residue (Y332) implicated in
binding to the PARG competitive inhibitor ADP-HPD is
also present in TcPARG [17,18,20,21].
Poly-ADPr chains degradation in higher eukaryotes is
carried out mainly by PARG, although ARH3 (ADP-
ribose hydrolase-like) and ADP-ribosyl protein lyase
have also been assigned accessory roles in pADPr
decomposition [3,22,23]. Searches performed in our
laboratory indicated that the evolutionary unrelated
ARH3 proteins would be absent in T. cruzi genome. We
cannot rule out the possible existence of another
structurally and sequence-unrelated hydrolase protein
that could be involved in pADPr metabolism in these
parasites.
TcPARG expression was demonstrated to be
differential between developmental stages in T. cruzi
and throughout the different phases of the cell cycle.
TcPARG protein levels raise up to hour 8 after
hydroxyurea arrest relief, period included in the S-
phase, in which nuclear DNA and kDNA replication is
taking place. Remarkably, in this period as well, larger
amounts of pADPr were detected in this
trypanosomatid (unpublished data). We have observed,
between hours 8-14 in synchronized epimastigotes, the
appearance of proteins of lower molecular weights than
TcPARG. Given that alternative splicing in these
parasites does not occur, this result could be due to
specific protease cleavage events as a possible control
or to unspecific protein degradation. Affar and co-
workers have reported PARG degradation mediated by
caspase 3 [24]. Since up to date these proteases were
not described in trypanosomatids, we cannot rule out
other regulatory mechanisms, which will need to be
addressed in the future.
In higher eukaryotes, PARG has been reported to
change its subcellular localization in response to DNA
damaging agents: in the absence of single strand
breaks on the DNA, PARG is found in the cytoplasm of
the cell. However, when the cells are exposed to an
agent capable of causing lesions on the genetic
material, PARG migrates from the cytoplasm into the
nucleus, where high amounts of pADPr are produced.
This is thought to be a regulatory mechanism of the
glycohydrolase activity displayed by this enzyme. As
shown in the present work, in T. cruzi we have
observed the nuclear localization of TcPARG despite
the absence of DNA damage. For hPARG, shuttling
between nucleus and cytoplasm has been also reported
during the cell cycle as well as its localization to the
centrosomes in mitosis [25] and different nuclear and
extranuclear isoforms have been described [26–28].
Our results are in dissonance with this report since in
synchronized epimastigotes we have found that
TcPARG was present mainly in the nucleus during all
phases, G1, S and G2/M (Figure S1 C). We have
previously reported that TcPARP migrates to the
nucleus after a genotoxic insult in correlation with the
detection of polymer formation in this organelle [13].
The localization of these enzymes could be a strategy
for the regulation of the pADPr synthesizing-
degradating activity. These results are in agreement
with the necessity of PARG for pADPr degradation since
pADPr is metabolized mainly by this enzyme. A deeper
evaluation of the possible presence of TcPARG in the
mitochondrion of T. cruzi needs to be addressed. It is
possible that this enzyme could be implicated in the
regulation of mitochondrial enzymes, since we have
obtained many of these proteins pADPrilated by
immunoprecipitation, even in the absence of damaging
agents (unpublished data).
The signal that leads these enzymes to its particular
localization has not been determined, precise
subcellular localization motifs have not been described
yet in trypanosomatids. This finding posses a new
question regarding the mechanism through which the
activity of PARG and PARP is regulated in these
parasites. Further studies will be necessary to find the
signals that control the subcellular localization of both
TcPARP and TcPARG, in order to better understand the
particular distribution of these enzymes.
The PARG inhibitors tested here had an impact on T.
cruzi epimastigotes growth ratio, at least in culture.
The unspecific inhibitor DEA [29] reduced parasite
growth by about 35% at concentrations of 1 µM.
Although this compound might be affecting other
cellular processes, these results were supported by the
similar effect observed when the more specific inhibitor
ADP-HPD [30] was used. This effect is observed on
epimastigote cultures after 4 days of incubation in the
presence of the PARG-inhibiting compounds, pointing
out that the reduction of the growth ratio might be
related to the accumulation of DNA damages
throughout time due to the lack of an appropriately
functioning pADPr metabolism. The diminished growth
ratio displayed by the epimastigotes incubated in the
presence of PARG inhibitors has shown to be
independent of the culture phase, since both log-phase
and stationary phase cultures showed reduced growth
only after the 4-day incubation period.
The impact of DEA and ADP-HPD on epimastigote
growth ratio is moderate, showing only a partial
reduction of epimastigotes ability to survive or
duplicate. It has been pointed out that PARG inhibitors
show low cell permeability [31,32] and we have also
encountered a partial inhibition of pADPr degradation in
vivo in the presence of these compounds, what may
explain the results here obtained.
As we have shown previously, TcPARP activation also
leads to automodification by ADP-ribosylation, which
results in PARP inhibition [12]. PARG is involved in the
removal of polymers from different proteins, including
PARP itself; in this regard, inhibition of PARG could
extend the half-life of polymers on TcPARP and other
proteins in the nucleus and hence modify cell cycle
progression. As reported in this work, the presence of
PARG inhibitors caused an alteration in the progression
Importance of PARG for T.cruzi Infection
PLOS ONE | www.plosone.org 12 June 2013 | Volume 8 | Issue 6 | e67356
of the cell cycle in T. cruzi epimastigotes. This result is
in agreement with those obtained for 3-
aminobenzamide-treated cells, in which PARP was
inhibited and a lower growth rate was observed,
suggesting that pADPr metabolism could play a role in
the earlier phase of epimastigotes growth, even in the
absence of exogenous DNA damage [13]. Therefore, an
explanation for the data here obtained is that inhibiting
TcPARG leads to the depletion of the pool of non-
modified TcPARP available to repair other sites of
damage that are spontaneously occurring. Thus, an
indirect effect of PARG inhibition is the shutdown of
PARP activity. Studies on PARG knockout mice suggest
that absence of PARG activity may represent a strategy
to enhance the effectiveness of chemotherapeutic
agents and that PARG inhibitors might indirectly
compromise PARP function in the repair of DNA
damage induced by certain agents [33,34].
In view of the scarcity of information available on the
role of pADPr metabolism in trypanosomatids, our
report about the existence of a PARG in T. cruzi as well
as the possible role here reported for TcPARG in the
cell cycle of these parasites contributes to this subject
and other functional studies should be considered in
order to fully understand the role of poly(ADP-ribosyl)
ation in this parasites. Nevertheless, the most notable
contribution achieved by the present work is given by
the determination of the possible role that host cell
pADPr metabolism could be playing in the cell infection
process perpetrated by these parasites.
We have recently reported that PARP-1 silenced cells
show lower susceptibility to T. cruzi infection and that a
similar effect is observed in the presence of PARP
inhibitors. However, in neither case the amastigote to
trypomastigote differentiation process, or the
amastigote intracellular replication seemed to be
deeply affected, since trypomastigotes can be readily
found in the supernatant of these cultures [14]. The
results here presented suggest that PARG inhibitors
could be affecting the cell cycle progression of this
trypanosomatid and slowing down its growth, as
observed in the epimastigote form. Nevertheless, the
poly(ADP-ribose) glycohydrolase activity from the host
cell seems to be playing a fundamental role during the
process of infection. Our experiments, in which hPARG
was inhibited with DEA or knocked down by iRNA,
showed that the absence of this enzymatic activity has
a deeper impact on T. cruzi infection than the absence
of PARP activity. This result could potentially indicate
that additional mechanisms other than those affected
by PARP inhibition could be affected by PARG genetic
or chemical ablation.
The absence of the PARG enzyme achieved by iRNA
in A549 cells demonstrated a drastic reduction in the
percentage of infected cells and in the number of
amastigotes per cell when compared to wild type A549
infected cultures. However, a significant amount of
trypomastigotes could still be detected in the
supernatant of these cultures. In chemically PARG
inhibited host cells, not only a significant reduction in
the percentage of infected cells and in the number of
amastigotes per cell was observed, but also a nearly
complete absence of trypomastigotes in the culture
supernatant was found, leading to a practically total
abrogation of the infection process. The difference
between these results highlights the crucial role of host
cell PARG for the establishment and continuity of T.
cruzi infection but also points out a possible role of the
parasite enzyme; the implication of TcPARG in the
intracellular amastigote replication and/or amastigote
to trypomastigote differentiation processes cannot be
ruled out.
Ba et al [35] reported that human cardiomyocytes
produce reactive oxygen species (ROS) and
inflammatory cytokines in response to Trypanosoma
cruzi. Poly-ADPr formation and pADPrylation of
mitochondrial membranes provide a secondary signal
resulting in a positive feedback cycle of mitochondrial
ROS production, DNA damage, and PARP-1/pADPr
activation. ROS, either through direct modulation of
cytosolic NF-κB or via PARP-1-dependent pADPr
modification of p65-interacting nuclear proteins,
contribute to cytokine gene expression and could be
pointing out a link between ROS and inflammatory
responses providing a clue to the pathomechanism of
sustained inflammation in Chagas’ disease. Moreover,
Pinto et al [36] show that the TNF/NF-kB axis
participates in T. cruzi invasion of non-professional
phagocytic epithelial cell lines, resulting in increased
number of intracellular parasites, leading to the
conclusion that NF-κB activation in non-immune cells
elicited by paracrine factors released by immune cells
represents a mechanism by which T. cruzi persists in
the host. It has been recently published that
phosphorylated cytoplasmic IκBα is diminished in
shRNA PARG Lovo cells and consequently the
intranuclear expression of NF-κB p65 and the total
protein expression of the latter are decreased [37]. Al-
Halabi et al. [38] have demonstrated that treatment
with gallotannins inhibits NF-κB and slows the growth
of human colon cancer xenografts. PARG inhibitor
(gallotannin-GT) in A549 cells suppressed expressions
of cytokines and chemokines blocking the activation of
transcription factors NF-κB and activator protein-1
(AP-1) [39].
PARG activity in the host cell, because of its endo-
and exo-glycosidase activity, could generate both free
ADP-ribose or pADPr. Many evidences suggest that
pADPr may exert different biological activities and a
vast bibliography has been reported by Althaus et al.
[40]. Apart from recruiting multiprotein complexes,
pADPr may regulate the functions of specific protein
domains, such as DNA binding or protein–protein
interaction domains, catalytic activities, and post-
translational modification sites. Moreover, pADPr size
selectivity has been also demonstrated, thus adding
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more complexity to a pADPr-mediated regulatory
mechanism. Hence, noncovalent interactions of pADPr
with proteins are an important element of the
intracellular-signaling network, which deserves
attention. Blenn et al. [41] hypothesize that PARG could
control Ca2+ shifts by converting pADPr into ADP-ribose,
a possible activator of TRPM2 channels in vitro.
Transient changes of intracellular calcium
concentration could play a role in the invasion process
and further studies have to be done to put insight to
the signal mechanisms involved. We are carrying out
experiments in order to better understand the
mechanism of the invasion facilitated by inflammatory
soluble factors and its relationship with pADPr
metabolism.
Investigating the biological role of PARG enzyme has
been challenging, since specific cell-permeable
inhibitors are not available. Natural plant tannins like
green tea polyphenols have been described, among
other effects such as antioxidant activity, to inhibit
PARG activity, with consequent accumulation of pADPr,
and to induce growth inhibition and apoptosis in cancer
cell lines [42–44]. Guida et al. [45] described the
trypanocidal effects of compounds extracted from
Green tea gallocatechin gallate and epigallocatechin
gallate on the two clinically relevant forms of T. cruzi.
Recently PARG inhibitors has been suggested for
alternative specific treatment for BRCA2-deficient and
other HR-deficient tumors as single therapy [43], and
the inhibitor GPI16552 has also been used previously in
combination with the methylating agent temozolomide
to reduce tumor cell growth, metastasis and prolong
life in mice injected subcutaneously or intracranially
with B16 melanoma cells [46]. This demonstrates that
PARG inhibitors can be effectively used in an animal
model without excessive systemic toxicity. Lately PARG
is emerging as pharmacological target due to its low
cellular abundance and new PARG inhibitors like
modified salicylanilides [32] or rhodanine based
compounds are being synthesized [31]. The aims in this
field should be to develop new compounds that gather
the desirable characteristics of ADP-HPD and DEA: the
high specificity of the former inhibitor and the
permeability of the latter.
The complexity of the relationship between PARP,
PARG and cell invasion clearly deserves further
investigation if PARP and PARG inhibitors are to be
utilized to their fullest potential in T. cruzi infection.
Supporting Information
Figure S1.  Analysis of Trypanosoma cruzi
poly(ADP-ribose) glycohydrolase expression over
cell cycle.  (A) Northern blot analysis of Trypanosoma
cruzi CL Brener epimastigotes in synchronized cultures.
Cultures with a density of 107 parasites were incubated
in the presence of hydroxyurea 15 mM for 20 hs. After
this period, parasites were washed with PBS,
resuspended in LIT medium and samples were drawn
and analyzed by flow cytometry. Total RNA (10µg) from
the parasites throughout the cell cycle was subjected
to electrophoresis, transferred and hybridized with a
radiolabeled probe corresponding to the full length of
the coding region. rRNA was used as loading control.
(B) Western blot analysis of TcPARG in T. cruzi
epimastigotes. Protein extracts (35 µg) were
electrophorezed and transferred to a nitrocellulose
membrane and revealed with a 1:10000 dilution of
polyclonal antibody against TcPARG followed by 1:6000
anti-mouse HRP conjugated antibody. β-tubulin was
used as loading control. (C) Immunolocalization of
TcPARG. Epimastigotes were fixed, treated with
primary antibody (1:500) and Alexa Fluor 488 goat
anti-mouse IgG antibody (1:600). Coverslips were
washed with distilled water and mounted in Mowiol and
then visualized using an Olympus BX41 microscope.
Figure S2.  Sub-cellular localization of
Trypanosoma cruzi poly(ADP-ribose)
glycohydrolase.  T. cruzi CL Brener transgenic
epimastigotes carrying a copy of RED protein gene (A–
D) or the RED-TcPARG fusion gene (E–H) in the pTREX
expression vector were fixed for 25 min with 3.8%
(W/V) formaldehyde in PBS at 4°C, mounted in Mowiol
and visualized using an Olympus BX41 microscope.
Cells were counterstained with DAPI to identify nuclear
DNA and kinetoplastid (B,F). D and H show a merge
between RED protein and DAPI signals. H, shows
TcPARG and nuclear DNA colocalization. Bar: 10 µm.
Figure S3.  Effect of PARG inhibitors on T. cruzi
infection on Vero cells.  The infection was allowed to
proceed as described in Materials and Methods. In the
PARG inhibited samples, DEA was kept in the growth
medium at 1 µM throughout the experiment. At the
indicated days, cells were fixed and stained by May
Grünwald Giemsa technique. Cells were visualized
using an Olympus BX41 microscope.
Figure S4.  Effect of PARG inhibitors or PARG
absence in the A549 host cell on T. cruzi
infection.  The infection was allowed to proceed as
described in Materials and Methods. In the PARG
inhibited samples, DEA was kept in the growth medium
at 1 µM throughout the experiment. At day 6 post-
infection cells were fixed and stained by May Grünwald
Giemsa technique. Cells were visualized using an
Olympus BX41 microscope.
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